Genomic Health IDs Biomarker Leads for Breast Cancer Recurrence Prognosis via Next-Gen Sequencing
February 09, 2011
Genomic Health IDs Biomarker Leads for Breast Cancer Recurrence Prognosis via Next-Gen Sequencing
Through the hypothesis-generating exercise, enabled by Illumina's next-generation sequencing platform, the company identified "new candidate biomarkers linked to breast cancer recurrence from regions outside of the previously identified protein-coding sections of the genome."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NanoString on Track to Launch Breast Cancer Subtyping Test in EU with CE Mark, in US with FDA OK
August 15, 2012 / Pharmacogenomics Reporter - People in the News: Joffre Baker, Steven Shak, Felix Baker
August 1, 2012 / Clinical Sequencing News - Genomic Health to Launch NGS-based Somatic Cancer Mutation Detection Platform for Pharma Research
January 25, 2012 / Pharmacogenomics Reporter - Genomic Health Expanding Sales Force by 20 Percent; Starts Prostate Dx Studies
January 9, 2012 / GenomeWeb Daily News - Increasing Investment in Next-Gen Sequencing, Genomic Health Takes $2.8M Stake in Two Startups
May 4, 2011 / Clinical Sequencing News